← Back to headlines
AbbVie's Apogee Deal to Extend Immunology Dominance
AbbVie's $10.9 billion acquisition of Apogee is expected to strengthen its leadership in the immunology market, prompting analysis on whether it's a good time for investors to buy shares.
22 Jun, 22:56 — 22 Jun, 22:56
Sources
Showing 1 of 1 sources
